

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,041,424	08/20/1991	Saulnier et al.
	5,169,933	12/08/1992	Anderson et al.
	5,258,499	11/02/1993	Konigsberg et al.
	5,442,043	08/15/1995	Fukuta et al.
	5,869,045	02/09/1999	Hellstrom et al.
	5,922,754	07/13/1999	Burchett et al.
	6,126,965	10/03/2000	Kasid et al.
	6,191,290	02/20/2001	Safavy
	6,306,993	10/23/2001	Rothbard et al.
	6,316,024	11/13/2001	Allen et al.
	6,660,525	12/09/2003	Martin et al.
	6,713,454	03/30/2004	Ekwuribe et al.
	6,930,090	08/16/2005	Ekwuribe et al.
	7,153,946	12/26/2006	McChesney et al.
	7,208,174	04/24/2007	Huwlyer et al.
	7,557,182	07/07/2009	Beliveau et al.
	7,569,544	08/04/2009	Zankel et al.
	7,700,554	04/20/2010	Beliveau et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

U.S. PATENT DOCUMENTS			
	RE35,524	06/03/1997	Saulnier et al.
	2002/0086384	07/04/2002	Levine et al.
	2004/0146549	07/29/2004	Ben-Sasson et al.
	2004/0220132	11/04/2004	Kaemmerer
	2007/0149444	06/28/2007	Laakkonen et al.
	2007/0167365	07/19/2007	Beliveau et al.
	2007/0172462	07/26/2007	Bohn et al.
	2007/0197460	08/23/2007	Fougerolles et al.
	2008/199436	08/21/2008	Sawada
	2008/0299039	12/04/2008	Beliveau et al.
	2009/0016959	01/15/2009	Beliveau et al.
	2009/0082277	03/26/2009	Beliveau et al.
	2009/0246211	10/01/2009	Henri et al.
	2010/0256055	10/07/2010	Castaigne et al.
	2010/0297120	11/25/2010	Beliveau et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	CA 2421042	05/16/2002	Canada	
	CA 2637893	07/26/2007	Canada	
	CA 2638034	07/26/2007	Canada	
	EP 1466924	10/13/2004	EPO	
	GB 2360453	01/05/2000	United Kingdom	
	WO 96/31531	10/10/1996	WIPO	
	WO 96/39183	12/ 12/1996	WIPO	
	WO 96/40210	12/19/1996	WIPO	
	WO 97/40854	11/06/1997	WIPO	
	WO 97/40160	10/30/1997	WIPO	
	WO 99/46575	09/16/1999	WIPO	
	WO 00/01417	01/13/2000	WIPO	
	WO 01/30319	05/03/2001	WIPO	
	WO 2005/002515	01/13/2005	WIPO	
	WO 2007/020085	02/22/2007	WIPO	
	WO 2007/103515	09/13/2007	WIPO	
	WO 2007/030619	03/15/2007	WIPO	
	WO 2007/113172	10/11/2007	WIPO	
	WO 2008/012629	01/31/2008	WIPO	
	WO 2008/046228	04/24/2008	WIPO	
	WO 2008/144919	12/04/2008	WIPO	
	WO 2009/039188	03/26/2009	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 2009/046220	04/09/2009	WIPO	
	WO 2009/070597	06/04/2009	WIPO	
	WO 2009/079790	07/02/2009	WIPO	
	WO 2009/105671	08/27/2009	WIPO	
	WO 2009/127072	10/22/2009	WIPO	
	WO 2010/043047	04/22/2010	WIPO	
	WO 2010/043049	04/22/2010	WIPO	
	WO 2010/063122	06/10/2010	WIPO	
	WO 2010/063123	06/10/2010	WIPO	
	WO 2010/063124	06/10/2010	WIPO	
	WO 2010/069074	06/24/2010	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Akhtar et al., "Nonviral Delivery of Synthetic siRNAs in Vivo," <i>J. Clin. Invest.</i> 117:3623-3632 (2007).
	Anonymous, "Blood-Brain Barrier Tackled," < http://www.ecancermedicalscience.com/news-insider-news.asp?itemid=326 > October 22, 2008.
	Arpicco et al., "New Coupling Reagents for the Preparation of Disulfide Cross-Linked Conjugates with Increased Stability," <i>Bioconj. Chem.</i> 8:327-337 (1997).
	Banks, "Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity," <i>Curr. Pharm. Des.</i> 7:125-133 (2001).
	Banks, "The Blood-Brain Barrier as a Cause of Obesity," <i>Curr. Pharm. Des.</i> 14:1606-1614 (2008).
	Barakat et al., "Modulation of P-Glycoprotein Function by Caveolin-1 Phosphorylation," <i>J. Neurochem.</i> 101: 1-8 (2007).
	Bertrand et al., "Transport Characteristics of a Novel Peptide Platform for CNS Therapeutics," <i>J. Cell Mol. Med.</i> published online October 10, 2009. (available at http://dx.doi.org/10.1111/j.1582-4934.2009.00930.x)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bicamumpaka et al., "In Vitro Cytotoxicity of Paclitaxel-Transferrin Conjugate on H69 Cells," <i>Oncol. Rep.</i> 5:1381-1383 (1998).
	Boado, "Blood-brain Barrier Transport of Non-viral Gene and RNAi Therapeutics," <i>Pharm. Res.</i> 24:1772-1787 (2007).
	Boules et al., "Bioactive Analogs of Neurotensin: Focus on CNS Effects," <i>Peptides.</i> 27:2523-2533 (2006).
	Castex et al., "2-Pyrrolinodoxorubicin and Its Peptide-vectorized Form Bypass Multidrug Resistance," <i>Anticancer Drugs.</i> 15:609-617 (2004).
	Chari et al., "Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs," <i>Acc. Chem. Res.</i> 41:98-107 (2008).
	Che et al., "New Angiopep-Modified Doxorubicin (ANG1007) and Etoposide (ANG1009) Chemotherapeutics with Increased Brain Penetration," <i>J. Med. Chem.</i> 53:2814-2824 (2010).
	Coon et al., "Solutol HS 15, Nontoxic Polyoxyethylene Esters of 12-hydroxystearic Acid, Reverses Multidrug Resistance," <i>Cancer Res.</i> 51:897-902 (1991).
	D'Onofrio et al., "Glycomimetics as Decorating Motifs for Oligonucleotides: Solid-phase Synthesis, Stability, and Hybridization Properties of Carbopeptoid-oligonucleotide Conjugates," <i>Bioconjug. Chem.</i> 16:1299-1309 (2005).
	Demeule et al., "Drug Transport to the Brain: Key Roles for the Efflux Pump P-Glycoprotein in the Blood-Brain Barrier," <i>Vascul. Pharmacol.</i> 38:339-348 (2002).
	Demeule et al., "Identification and Design of Peptides As a New Drug Delivery System For the Brain," <i>J. Pharmacol. Exp. Ther.</i> 324:1064-1072 (2008).
	Demeule et al., "Involvement of the Low-Density Lipoprotein Receptor-Related Protein in the Transcytosis of the Brain Delivery Vector Angiopep-2," <i>J. Neurochem.</i> 106:1534-1544 (2008).
	Dooley et al., "An All D-amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library," <i>Science.</i> 266: 2019-2022 (1994).
	Eigenbrot et al., "X-Ray Structure of Glial Cell-Derived Neurotrophic Factor at 1.9 Å Resolution and Implications for Receptor Binding," <i>Nat. Struct. Biol.</i> 4:435-438 (1997).
	Gabius et al., "Targeting of Neoglycoprotein-Drug Conjugates to Cultured Human Embryonal Carcinoma Cells," <i>J. Cancer Res. Clin. Oncol.</i> 113:126-130 (1987).
	Garsky et al., "The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy," <i>J. Med. Chem.</i> 44: 4216-4224 (2001).
	Gelmon, "The Taxoids: Paclitaxel and Docetaxel," <i>Lancet.</i> 344:1267-1272 (1994).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Gewirtz, "A Critical Evaluation of the Mechanisms of Action Proposed For the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin," <i>Biochem. Pharmacol.</i> 57:727-741 (1999).
	Gottschalk et al., "Protein Self-Association in Solution: The Bovine Pancreatic Trypsin Inhibitor Decamer," <i>Biophys. J.</i> 84: 3941-3958 (2003).
	Harkavyi et al., "Glucagon-Like Peptide 1 Receptor Stimulation Reverses Key Deficits in Distinct Rodent Models of Parkinson's Disease," <i>J. Neuroinflammation.</i> 5:19 (2008) (pages 1-9).
	Huang et al., "Targeting Delivery of Paclitaxel into Tumor Cells via Somatostatin Receptor Endocytosis," <i>Chem. Biol.</i> 7:453-461 (2000).
	Jodoin et al., "P-Glycoprotein in Blood-Brain Barrier Endothelial Cells: Interaction and Oligomerization With Caveolins," <i>J. Neurochem.</i> 87:1010-1023 (2003).
	Kalra, "Central Leptin Insufficiency Syndrome: An Interactive Etiology for Obesity, Metabolic and Neural Diseases and for Designing New Therapeutic Interventions," <i>Peptides.</i> 29:127-138 (2008).
	Karyekar et al., "Zonula Occludens Toxin Increases the Permeability of Molecular Weight Markers and Chemotherapeutic Agents Across the Bovine Brain Microvessel Endothelial Cells," <i>J. Pharm. Sci.</i> 92:414-423 (2003).
	Ke et al., "Gene Delivery Targeted to the Brain Using an Angiopep-Conjugated Polyethyleneglycol-Modified Polyamidoamine Dendrimer," <i>Biomaterials.</i> 30:6976-6985 (2009) (pp. 1-10).
	Kilic et al., "Intravenous TAT-GDNF is Protective after Focal Cerebral Ischemia in Mice," <i>Stroke.</i> 34: 304-1310 (2003).
	Kirsch et al., "Anti-Angiogenic Treatment Strategies for Malignant Brain Tumors," <i>J. Neurooncol.</i> 50:149-163 (2000).
	Kounnas et al., "LDL Receptor-Related Protein, a Multifunctional ApoE Receptor, Binds Secreted Beta-Amyloid Precursor Protein and Mediates Its Degradation," <i>Cell.</i> 82:331-340 (1995).
	Koziara et al., "In Situ Blood-Brain Barrier Transport of Nanoparticles," <i>Pharma. Res.</i> 20:1772-1778 (2003).
	Kreuter, "Nanoparticulate Carriers for Drug Delivery to the Brain," in <i>Nanoparticles as Drug Carriers</i> , Chapter 24, pp. 527-547, Torchilin VP, Imperial College Press, London (2006).
	Kreuter et al., "Direct Evidence That Polysorbate-80-Coated Poly (Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS Via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles," <i>Pharm. Res.</i> 20:409-416 (2003)
	Kumar et al., "Transvascular Delivery of Small Interfering RNA to the Central Nervous System," <i>Nature.</i> 448:39-43 (2007).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Lewis et al., "Maleimidocysteineamido-DOTA Derivatives: New Reagents for Radiometal Chelate Conjugation to Antibody Sulfhydryl Groups Undergo pH-Dependent Cleavage Reactions," <i>Bioconj. Chem.</i> 9:72-86 (1998).
	Mathupala, "Delivery of Small Interfering RNA (siRNA) to the Brain," <i>Exp. Opin. Ther. Pat.</i> 19:137-140 (2009).
	Mazel et al., "Doxorubicin-Peptide Conjugates Overcome Multidrug Resistance," <i>Anticancer Drugs.</i> 12:107-116 (2001).
	Moestrup et al., "Evidence That Epithelial Glycoprotein 330/Megalin Mediates Uptake of Polybasic Drugs," <i>J. Clin. Invest.</i> 96:1404-1413 (1995).
	Moore et al., "The Role of Flexible Tethers in Multiple Ligand-Receptor Bond Formation Between Curved Surfaces," <i>Biophys. J.</i> 91:1675-1687 (2006).
	Muratovska et al., "Conjugate For Efficient Delivery of Short Interfering RNA (siRNA) Into Mammalian Cells," <i>FEBS Lett.</i> 558:63-68 (2004).
	Niola et al., "A Plasmid-Enclosed VEGF siRNA Reduces Glioblastoma Angiogenesis and Its Combination With Interleukin-4 Blocks Tumor Growth In a Xenograft Mouse Model," <i>Canc. Biol. Ther.</i> 5:2:174-179 (2006).
	Pardridge "Drug Targeting to the Brain," <i>Pharm. Res.</i> 24:1733-1744 (2007).
	Peri et al., "D-Glucose as a Regioselectively Addressable Scaffold For Combinatorial Chemistry on Solid Phase," <i>J. Carbohydr. Chem.</i> 22:57-71 (2003).
	Qu et al., "Carbohydrate-Based Micelle Clusters Which Enhance Hydrophobic Drug Bioavailability by Up to 1 Order of Magnitude," <i>Biomacromolecules.</i> 7:3452-3459 (2006).
	Rawat et al., "Lipid Carriers: A Versatile Delivery Vehicle For Proteins and Peptides," <i>Yakugaku Zasshi.</i> 128:269-280 (2008).
	Régina et al., "Antitumor Activity of ANG 1005, A Conjugate Between Paclitaxel and the New Brain Delivery Vector Angiopep-2," <i>Br. J. Pharmacol.</i> 155:185-197 (2008).
	Rouselle et al., "New Advances in the Transport of Doxorubicin Through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy," <i>Mol. Pharmacol.</i> 57:679-686 (2000).
	Saito et al., "Drug Delivery Strategy Utilizing Conjugation Via Reversible Disulfide Linkages: Role and Site of Cellular Reducing Activities," <i>Adv. Drug Deliv. Rev.</i> 55:199-215 (2003).
	Samson et al., "Gene Therapy for Diabetes: Metabolic Effects of Helper-Dependent Adenoviral Exendin 4 Expression in a Diet-Induced Obesity Mouse Model," <i>Mol. Ther.</i> 16:1805-1812 (2008) (pages 1-18).
	Steiniger et al., "Chemotherapy of Glioblastoma in Rats Using Doxorubicin-Loaded Nanoparticles," <i>Int. J. Cancer.</i> 109: 759-767 (2004).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/541,304
	Applicant	Richard Beliveau et al.
	Filing Date	October 6, 2008
	Group	1654
	IDS Filed	February 23, 2011

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Takei et al., "A Small Interfering RNA Targeting Vascular Endothelial Growth Factor As Cancer Therapeutics," <i>Cancer. Res.</i> 64:3365-3370 (2004).
	Trail et al., "Cure of Xenografted Human Carcinomas By BR96-Doxorubicin Immunoconjugates," <i>Science.</i> 261:212-215 (1993).
	Turner et al., "RNA Targeting With Peptide Conjugates of Oligonucleotides, siRNA and PNA," <i>Blood Cells Mol. Dis.</i> 38:1-7 (2007).
	Uekita et al., "Membrane-Type 1 Matric Metalloproteinase Cytoplasmic Tail-Binding Protein-1 Is a New Member of the Cupin Superfamily. A Possible Multifunctional Protein Acting As An Invasion Suppressor Down-Regulated in Tumors," <i>J. Biol. Chem.</i> 279:12734-12743 (2004).
	Uekita et al., "Cytoplasmic Tail-Dependent Internalization of Membran-Type 1 Matrix Metalloproteinase is Important For Its Invasion-Promoting Activity," <i>J Cell Biol.</i> 155:1345-1356 (2001).
	Veronese et al., "PEGylation, Successful Approach to Drug Delivery," <i>Drug Discov. Today.</i> 10:1451-1458 (2005).
	Wang et al., "DNA/Dendrimer Complexes Mediate Gene Transfer Into Murine Cardiac Transplants <i>ex Vivo</i> ," <i>Mol. Ther.</i> 2: 602-608 (2000).
	Xu et al., "In Vitro and In Vivo Evaluation of Actively Targetable Nanoparticles For Paclitaxel Delivery," <i>Int. J. Pharm.</i> 288:361-368 (2005).
	Zhang et al., "siRNA-Containing Liposomes Modified With Polyarginine Effectively Silence the Targeted Gene," <i>J. Control Release.</i> 112:229-239 (2006).
	Zhang et al., "Silencing The Epidermal Growth Factor Receptor Gene With RNAi May Be Developed As a Potential Therapy for Non Small Cell Lung Cancer," <i>Genet. Vaccines Ther.</i> 3:1-12 (2005).
	Zhang et al., "Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer," <i>Clin. Cancer Res.</i> 10:3667-3677 (2004).
	European Patent Office Communication Containing Extended Search Report of Application Number 10009847.4-1216, Dated November 15, 2010 (8 pages).
	Reply to Office Action pertaining to U.S. Patent Application No.: 11/185,947, Mailed June 6, 2008 (14 pages).
	Reply to Office Action pertaining to U.S. Patent Application No.: 11/185,947, Filed February 6, 2009 (11 pages).
	European Patent Office Communication pertaining to European Patent Application No.: 05 770 546.9, Dated January 11, 2010 (5 pages).
	Response to European Patent Office Communication pertaining to European Patent Application No.: 05 770 546.9, Filed July 21, 2010 (16 pages).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50546/002002
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>		Serial No.	10/541,304
		Applicant	Richard Beliveau et al.
		Filing Date	October 6, 2008
		Group	1654
(37 C.F.R. § 1.98(b))		IDS Filed	February 23, 2011

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	European Patent Office Communication pertaining to European Patent Application No.: 05 770 546.9, Dated January 18, 2011 (4 pages).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	